Vishal Sikri was named Senior Vice President, Product of Myriad Genetics Inc, effective September 16, 2026. As of November 6, 2026, Myriad Genetics Inc has reported 3 leadership change filings to the SEC under Item 5.02 of Form 8-K, from June 23, 2026 to October 9, 2026, naming 1 appointment (Form 8-K, September 16, 2026).
MYRIAD GENETICS INC named a new Senior Vice President, Product on Sep 16. 30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Myriad Genetics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-10-09
- · In / out: In · Person: Vishal Sikri · Role: Senior Vice President, Product · Effective: 2026-09-16 · 8-K, 2026-09-16
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-06-23
Myriad Genetics Inc reported changes in 3 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-06-23 to 2026-10-09. They name 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Myriad Genetics Inc files it.
Also on the record for Myriad Genetics Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 27, 2026 | Stake report, Schedule 13G/A, by BlackRock Portfolio Management LLC | 8.6% of the class | 5%+ stakes | Source |
| September 4, 2026 | Stake report, Schedule 13G, by BlackRock Portfolio Management LLC | 10.4% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G, by Vestal Point Capital, LP | 6.1% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by GLENVIEW CAPITAL MANAGEMENT, LLC | — | 5%+ stakes | Source |
| August 7, 2026 | Stake report, Schedule 13G, by STATE STREET CORPORATION | 5.3% of the class | 5%+ stakes | Source |
| May 12, 2026 | Stake report, Schedule 13G, by STATE STREET CORPORATION | 4.7% of the class | 5%+ stakes | Source |
| April 7, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 8.5% of the class | 5%+ stakes | Source |
| March 27, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| February 11, 2026 | Stake report, Schedule 13G/A, by Millennium Management LLC | 7.2% of the class | 5%+ stakes | Source |
| February 9, 2026 | Stake report, Schedule 13G, by STATE STREET CORPORATION | 6.4% of the class | 5%+ stakes | Source |
| January 13, 2026 | Stake report, Schedule 13G, by GLENVIEW CAPITAL MANAGEMENT, LLC | 5.3% of the class | 5%+ stakes | Source |
| November 12, 2025 | Stake report, Schedule 13G/A, by Barclays PLC | 4.23% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Myriad Genetics Inc now and the warning signs.
Free to see. No signup.
Keep reading
More on Myriad Genetics Inc and the records around it.
Myriad Genetics Inc elsewhere on the record
- 5%+ stake filings Oct 2026
- Who owns it
Companies that share a holder
- GLENVIEW CAPITAL MANAGEMENT, LLC also filed stake reports on 6 other companies: Surgery Partners, Inc. (Oct 2026), Butterfly Network, Inc. (Aug 2026), DXC Technology Co (Aug 2026)
- DISCIPLINED GROWTH INVESTORS INC /MN also filed stake reports on 10 other companies: Alarm.com Holdings, Inc. (Aug 2026), Kornit Digital Ltd. (Aug 2026), Stitch Fix, Inc. (Aug 2026)
- Vestal Point Capital, LP also filed stake reports on 27 other companies: Alto Neuroscience, Inc. (Aug 2026), iBio, Inc. (Aug 2026), Immunocore Holdings plc (Aug 2026)
Watch Myriad Genetics Inc
Get an email when Myriad Genetics Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Myriad Genetics Inc?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Myriad Genetics Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Myriad Genetics Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
15 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 20 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-10-09 | Reported | not named in the filing | 8-K, 2026-10-09 | ||
| 2026-09-16 | In | Senior Vice President, Product | 2026-09-16 | 8-K, 2026-09-16 | |
| 2026-06-23 | Reported | not named in the filing | 8-K, 2026-06-23 |
Who leads Myriad Genetics Inc, as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Senior Vice President, Product: Vishal Sikri, appointed, effective 2026-09-16 (filed 2026-09-16).
New leaders reset buying decisions — get the Full Report on Myriad Genetics Inc: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Senior Vice President, Product at Myriad Genetics Inc, with the record behind each one.
Find candidates like Product at Myriad Genetics IncEvery change, in the filing's words
Reported
Mr. Donnelly's separation from employment occurred at the close of business on September 21, 2026 (the "Separation Date").
- On October 6, 2026, Myriad Genetics, Inc. (the "Company") entered into a Separation Agreement and Release of Claims (the "Separation Agreement") with Brian Donnelly, the Company's former Chief Commercial Officer.
- As previously disclosed, Mr. Donnelly departed from his position as Chief Commercial Officer of the Company, effective September 16, 2026.
- The Separation Agreement becomes effective on October 14, 2026, provided that Mr. Donnelly does not revoke the Separation Agreement prior to such date.
- Pursuant to the terms of the Separation Agreement, in consideration for, among other things, his compliance with certain restrictive covenants, including customary non-solicitation and non-disparagement covenants, and a typical release of claims against the Company, Mr. Donnelly will receive a lump sum severance payment of $1,322,294.
- The foregoing severance and other consideration payable to Mr. Donnelly is being made pursuant to the terms of Mr. Donnelly's Severance and Change of Control Agreement.
Appointed: Vishal Sikri, Senior Vice President, Product, effective 2026-09-16
On September 15, 2026, the Company's Board of Directors (the "Board") appointed Vishal Sikri, currently serving as the Company's Senior Vice President, Product, as the Company's Executive Vice President, Commercial, effective September 16, 2026.
- On September 16, 2026, Myriad Genetics, Inc. (the "Company") announced that, effective September 16, 2026, Brian Donnelly no longer serves as Chief Commercial Officer of the Company.
- Mr. Donnelly is expected to remain as a non-executive employee of the Company through September 21, 2026 to assist in the transition of his responsibilities.
- Mr. Sikri's appointment as Executive Vice President, Commercial, was announced by the Company via press release on September 16, 2026.
Reported
On June 17, 2026, Daniel M. Skovronsky M.D., Ph.D., a member of the Board of Directors of Myriad Genetics, Inc. (the "Company") notified the Company that he is resigning as a director, effective immediately.
- Dr. Skovronsky's resignation was not a result of any disagreement with the Company or due to any matter relating to the Company's operations, policies, or practices.
Tools for this story
Each opens in a new tab, filled in for Myriad Genetics Inc. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.